An interventional study of Pharmacokinetic study in Citrate Toxicity, Regional Citrate Anticoagulation and Liver Failure, Acute, sponsored by Chulalongkorn University. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-14.
Sponsored by Chulalongkorn University · Not applicable, Interventional, and Diagnostic
Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA).
This study aimed to evaluate citrate PKs, metabolic complications, and clinical outcomes among critically ill acute liver failure (ALF) and acute on top chronic liver failure (ACLF) patients receiving CRRT.
445 studies on the registry are indexed under Liver Failure; 69 are open to participants now.
This study's enrollment of 20 is below the median of 43 across 276 interventional studies indexed under Liver Failure.
Browse Liver Failure studies →Chulalongkorn University is the lead sponsor of 312 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Acute liver failure critically ill patients receiving CRRT
Diagnostic Test: Pharmacokinetic study
Acute on top chronic liver failure critically ill patients receiving CRRT
Diagnostic Test: Pharmacokinetic study
* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L * Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium * In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter
Citrate clearance
Citrate clearance by body
Time frame: 4 hours
Citrate accumulation
Number of total calcium to ionized calcium ratio \> 2.5 with acidosis with hypocalcemia
Time frame: 4 hours
Tmax
Time to maximum concentration of citrate at 2 hours
Time frame: 2 hours
Area under the time curve
Area under the plasma concentration-time curve of citrate
Time frame: 4 hours
Change of systemic ionized calcium
Change in systemic ionized calcium in arterial blood gas during study
Time frame: 4 hours
Change of ionized magnesium
Change in systemic ionized magnesium in arterial blood gas during study
Time frame: 4 hours
Change of bicarbonate
Change of bicarbonate in arterial blood gas during study
Time frame: 4 hours
Ratio of total calcium to systemic ionized calcium
Number of patients with total calcium to systemic ionized calcium \> 2.5 with or without metabolic acidosis
Time frame: 4 hours
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chulalongkorn University